Tourmaline Oil Corp. closed 7.6% below its 52-week high of C$70.83, which the company reached on February 21st.

Tourmaline Oil Corp. closed 6.2% below its 52-week high of C$70.83, which the company achieved on February 21st.

Phase 2 TRANQUILITY trial in patients with elevated high-sensitivity C-reactive protein and chronic kidney disease over-enrolled to 143 total participants, on track to report topline data in the ...

In a report released today, Laura Chico from Wedbush maintained a Buy rating on Tourmaline Bio (TRML – Research Report), with a price target of ...

H.C. Wainwright raised the firm’s price target on Tourmaline Bio (TRML) to $50 from $49 and keeps a Buy rating on the shares following the Q4 ...

My last article some years back noted that Charlie Lake had a lot of profit potential, and Tourmaline was there first. As the slide above shows, Charlie Lake has one of the best profit potentials ...

Fintel reports that on March 6, 2025, Wedbush initiated coverage of Tourmaline Bio (NasdaqGS:TRML) with a Outperform ...

Analysts at Wedbush issued their FY2024 EPS estimates for shares of Tourmaline Bio in a research note issued on Thursday, March 6th. Wedbush analyst L. Chico expects that the company will post ...

NEW YORK - Tourmaline Bio, Inc. (NASDAQ: TRML) reported a wider fourth quarter loss on Wednesday, as the clinical-stage biotech company ramped up spending on research and development. Shares fell 2% ...

After reviewing the many advantages of Xitox foot pads and considering the favorable reviews left by actual customers, we ...